Synageva BioPharma Corp Lands $12,000,000 New Financing Round

  • Feed Type
  • Date
    10/20/2009
  • Company Name
    Synageva BioPharma Corp
  • Mailing Address
    60 Hickory Drive Waltham, MA 02451
  • Company Description
    Synageva BioPharma’s ultimate goal is to improve patient lives by providing access to breakthrough novel, next generation (i.e. significantly improved), and certain follow on protein therapeutics. Synageva’s proprietary platform technologies, including SEPTM, provide a number of sustainable competitive advantages for developing and commercializing these therapeutics including: high expression levels, more efficient purification processes, significantly reduced costs of production, rapid scalability, and consistency of end product. Our platform has already demonstrated its ability to produce a wide array of human therapeutic proteins including monoclonal antibodies (mAbs), cytokines, and other biotherapeutics.
  • Website
    http://www.synageva.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $12,000,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    Proceeds purposes were not disclosed.
  • M&A Terms
  • Venture Investor
    New Leaf Venture Partners

Trending on Xconomy